Cargando…
Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders
Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240913/ https://www.ncbi.nlm.nih.gov/pubmed/37284319 http://dx.doi.org/10.3389/fphar.2023.1131354 |
_version_ | 1785053877633024000 |
---|---|
author | Alkhowaiter, Saad S. Alshahrani, Amani H. Almarzouqi, Hala F. Alonazi, Gadah K. Alhawassi, Tariq M. AlRasheed, Maha M. |
author_facet | Alkhowaiter, Saad S. Alshahrani, Amani H. Almarzouqi, Hala F. Alonazi, Gadah K. Alhawassi, Tariq M. AlRasheed, Maha M. |
author_sort | Alkhowaiter, Saad S. |
collection | PubMed |
description | Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients and Methods: We included 51 patients who received escitalopram for irritable bowel syndrome (n = 26), functional heartburn (n = 10), globus sensation (n = 10) or combined disorders (n = 5). We used an irritable bowel syndrome-severity scoring system IBS-SSS), GerdQ questionnaire and Glasgow Edinburg Throat Scale (GETS) to assess disease severity change before and after treatment. Results: The median age was 33 years (25th- 75th percentiles: 29–47), and 26 (50.98%) were males. Forty-one patients experienced side effects (80.39%), but most side effects were mild. The most common side effects were drowsiness/fatigue/dizziness (54.9%), xerostomia (23.53%), nausea/vomiting (21.57%) and weight gain (17.65%). IBS-SSS was 375 (255–430) and 90 (58–205) before and after treatment, respectively (p < 0.001). GerdQ score was 12 (10–13) before treatment and 7 (6–10) after treatment (p = 0.001). GETS score before treatment was 32.5 (21–46) and after treatment became 22 (13–31) (p = 0.002). Thirty-five patients refused to take the medications, and seven patients discontinued the medication. Possible causes of the poor compliance were fear of the medications and not being convinced of taking psychiatric medications for functional disorders (n = 15). Conclusion: Escitalopram could be a safe and effective treatment for functional gastrointestinal disorders. Targeting and managing factors leading to poor compliance could further improve the treatment outcome. |
format | Online Article Text |
id | pubmed-10240913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102409132023-06-06 Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders Alkhowaiter, Saad S. Alshahrani, Amani H. Almarzouqi, Hala F. Alonazi, Gadah K. Alhawassi, Tariq M. AlRasheed, Maha M. Front Pharmacol Pharmacology Background and study aims: The feasibility and barriars of escitalopram use in patients with functional gastrointestinal disorders (FGIDs) are still debated. We aimed to evaluate the feasibility, safety and efficacy and barriars of escitalopram use in managing FGIDs in the Saudi population. Patients and Methods: We included 51 patients who received escitalopram for irritable bowel syndrome (n = 26), functional heartburn (n = 10), globus sensation (n = 10) or combined disorders (n = 5). We used an irritable bowel syndrome-severity scoring system IBS-SSS), GerdQ questionnaire and Glasgow Edinburg Throat Scale (GETS) to assess disease severity change before and after treatment. Results: The median age was 33 years (25th- 75th percentiles: 29–47), and 26 (50.98%) were males. Forty-one patients experienced side effects (80.39%), but most side effects were mild. The most common side effects were drowsiness/fatigue/dizziness (54.9%), xerostomia (23.53%), nausea/vomiting (21.57%) and weight gain (17.65%). IBS-SSS was 375 (255–430) and 90 (58–205) before and after treatment, respectively (p < 0.001). GerdQ score was 12 (10–13) before treatment and 7 (6–10) after treatment (p = 0.001). GETS score before treatment was 32.5 (21–46) and after treatment became 22 (13–31) (p = 0.002). Thirty-five patients refused to take the medications, and seven patients discontinued the medication. Possible causes of the poor compliance were fear of the medications and not being convinced of taking psychiatric medications for functional disorders (n = 15). Conclusion: Escitalopram could be a safe and effective treatment for functional gastrointestinal disorders. Targeting and managing factors leading to poor compliance could further improve the treatment outcome. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10240913/ /pubmed/37284319 http://dx.doi.org/10.3389/fphar.2023.1131354 Text en Copyright © 2023 Alkhowaiter, Alshahrani, Almarzouqi, Alonazi, Alhawassi and AlRasheed. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Alkhowaiter, Saad S. Alshahrani, Amani H. Almarzouqi, Hala F. Alonazi, Gadah K. Alhawassi, Tariq M. AlRasheed, Maha M. Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title | Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title_full | Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title_fullStr | Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title_full_unstemmed | Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title_short | Feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
title_sort | feasibility, and barriers to use escitalopram in functional gastrointestinal disorders |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240913/ https://www.ncbi.nlm.nih.gov/pubmed/37284319 http://dx.doi.org/10.3389/fphar.2023.1131354 |
work_keys_str_mv | AT alkhowaitersaads feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders AT alshahraniamanih feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders AT almarzouqihalaf feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders AT alonazigadahk feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders AT alhawassitariqm feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders AT alrasheedmaham feasibilityandbarrierstouseescitalopraminfunctionalgastrointestinaldisorders |